Paolo Gontero

Active 2002–2025

209
Papers
18,863
Citations
68
h-index
188
i10-index

Citations

Citations per year for Paolo Gontero1993: 1 citations1999: 1 citations2001: 2 citations2003: 2 citations2005: 5 citations2006: 7 citations2007: 5 citations2008: 8 citations2009: 13 citations2010: 17 citations2011: 26 citations2012: 42 citations2013: 41 citations2014: 37 citations2015: 38 citations2016: 61 citations2017: 51 citations2018: 63 citations2019: 402 citations2020: 645 citations2021: 746 citations2022: 682 citations2023: 554 citations2024: 924 citations2025: 452 citations2026: 22 citations1994–1998: no citations, so these years are not shown2000: no citations, so this year is not shown2002: no citations, so this year is not shown2004: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,160 citing papers, 14.6% of this breakdownChina: 816 citing papers, 10.3% of this breakdownItaly: 786 citing papers, 9.9% of this breakdownGermany: 461 citing papers, 5.8% of this breakdownUnited Kingdom: 410 citing papers, 5.2% of this breakdownFrance: 375 citing papers, 4.7% of this breakdownNetherlands: 362 citing papers, 4.5% of this breakdownSpain: 286 citing papers, 3.6% of this breakdownAustria: 271 citing papers, 3.4% of this breakdownCanada: 261 citing papers, 3.3% of this breakdownJapan: 243 citing papers, 3% of this breakdownSwitzerland: 201 citing papers, 2.5% of this breakdown
0%14.6%Other 29.2%

Fields

  • Medicine80.4%
  • Biochemistry, Genetics and Molecular Biology12.6%
  • Immunology and Microbiology2.4%
  • Engineering1.3%
  • Neuroscience1.2%
  • Computer Science0.6%
  • Other1.5%

Topics

  • Bladder and Urothelial Cancer Treatments16.5%
  • Urinary and Genital Oncology Studies8.8%
  • Prostate Cancer Diagnosis and Treatment6.6%
  • Prostate Cancer Treatment and Research4.5%
  • Urinary Bladder and Prostate Research2.9%
  • Renal cell carcinoma treatment2.3%
  • Other58.4%

Coauthors

All papers

Open in search
  1. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)

    Authors: , , , , , , , , , , , , , , , , - European Urology 2021 cited by 1,623

  2. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update

    Authors: , , , , , , , , , , , , , , , , , , , - European Urology 2023 cited by 503

  3. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Andrea Haitel, Jean‐François Côté, Soha El Sheikh, Luca Lunelli, Ferrán Algaba, Isabel Alemany, Francesco Soria, Willemien Runneboom, Johannes Breyer, Jakko A. Nieuwenhuijzen, Carlos Llorente, Luca Molinaro, Christina A. Hulsbergen‐van de Kaa, Matthias Evert, Lambertus A. Kiemeney, James N’Dow, Karin Plass, Otakar Čapoun, Viktor Soukup, José L. Domínguez-Escrig, Daniel L. Cohen, Joan Palou, Paolo Gontero, Maximilian Burger, Richard Zigeuner, Amir Hugh Mostafid, Shahrokh F. Shariat, Morgan Rouprêt, Éva Compérat, Marko Babjuk, Bas W.G. van Rhijn - European Urology 2021 cited by 463

  4. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update

    Authors: , , , , , , , , , , , , , , , , , - European Urology 2019 cited by 1,327

  5. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update

    Authors: , , , , , , , , , , , , , , , , , - European Urology 2020 cited by 941

  6. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin

    Authors: , , , , , , , , , , , , , , , - European Urology 2015 cited by 640

  7. Repeat Transurethral Resection in Non–muscle-invasive Bladder Cancer: A Systematic Review

    Authors: , , , , , , , , - European Urology 2018 cited by 332

  8. 100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19

    Authors: , , , , , , , , , , , , , - Nature Reviews Urology 2021 cited by 147

  9. Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

    Authors: , , , , , , , , , , , - European Urology 2012 cited by 512

  10. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , - European Urology Oncology 2021 cited by 112

  11. Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

    Authors: , , , , , , , , , , - European Urology 2013 cited by 379

  12. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update

    Authors: , , , , , , , , , , , , , , , , , - European Urology 2024 cited by 239

  13. European Association for Endoscopic Surgery (EAES) consensus on Indocyanine Green (ICG) fluorescence-guided surgery

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nereo Vettoretto - Surgical Endoscopy 2023 cited by 114

  14. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non–muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review

    Authors: , , , , , , , , , , , , , , , , , - European Urology 2017 cited by 286

  15. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non–muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non–muscle-invasive Bladder Cancer Guidelines Panel Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Diana Turturica, Francesca Pisano, Francesco Soria, Otakar Čapoun, Lenka Bauerová, Michael Pešl, H.M. Bruins, Willemien Runneboom, Sonja Herdegen, Johannes Breyer, A. Brisuda, Ana Calatrava, J. Rubio‐Briones, Maximilian Seles, Sebastian Mannweiler, Judith Bosschieter, V.R.M. Kusuma, David Ashabere, Nicolai Huebner, Juliette Cotte, Laura S. Mertens, Daniel L. Cohen, Luca Lunelli, Olivier Cussenot, Soha El Sheikh, Dimitrios Volanis, Jean‐François Côté, Morgan Rouprêt, Andrea Haitel, Shahrokh F. Shariat, Hugh Mostafid, Jakko A. Nieuwenhuijzen, Richard Zigeuner, José L. Domínguez-Escrig, Jaromír Háček, Alexandre R. Zlotta, Maximilian Burger, Matthias Evert, Christina A. Hulsbergen ‐ van de Kaa, Antoine G. van der Heijden, Lambertus A. Kiemeney, Viktor Soukup, Luca Molinaro, Paolo Gontero, Carlos Llorente, Ferrán Algaba, Joan Palou, James N’Dow, Theodorus van der Kwast, Marko Babjuk, Richard J. Sylvester - European Urology Oncology 2021 cited by 101

  16. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ananya Choudhury, Éva Compérat, Simon J. Crabb, Stéphane Culine, Berardino De Bari, Willem de Blok, Pieter De Visschere, Karel Decaestecker, Konstantinos Dimitropoulos, José L. Domínguez-Escrig, Stefano Fanti, Valérie Fonteyne, Mark Frydenberg, Jurgen J. Fütterer, Georgios Gakis, Bogdan Geavlete, Paolo Gontero, Bernhard Grubmüller, S. Hafeez, Donna E. Hansel, Arndt Hartmann, Dickon Hayne, Ann Henry, Virginia Hernández, Harry W. Herr, Ken Herrmann, Peter Hoskin, J. Huguet, Barbara Alicja Jereczek‐Fossa, Rob Jones, Ashish M. Kamat, Vincent Khoo, Anne E. Kiltie, S. Krege, Sylvain Ladoire, Pedro C. Lara, Anna M. Leliveld, Estefanía Linares-Espinós, Vibeke Løgager, Anja Lorch, Yohann Loriot, Richard P. Meijer, Maria Carmen Mir, Marco Moschini, Hugh Mostafid, Arndt‐Christian Müller, Christoph R. Müller, James N’Dow, Andrea Necchi, Y. Neuzillet, Jorg R. Oddens, Jan Oldenburg, Susanne Osanto, Wim J.G. Oyen, Luís Pacheco‐Figueiredo, Helle Pappot, Manish I. Patel, Bradley R. Pieters, Karin Plass, Mesut Remzi, Margitta Retz, Jonathan Richenberg, Michael Rink, Florian Roghmann, Jonathan E. Rosenberg, Morgan Rouprêt, Olivier Rouvière, Carl Salembier, Antti Salminen, Paul Sargos and 21 more - European Urology 2019 cited by 192

  17. Role of HLA-G and extracellular vesicles in renal cancer stem cell-induced inhibition of dendritic cell differentiation

    Authors: , , , , , , , - BMC Cancer 2015 cited by 128

  18. Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI)

    Authors: , , , , , , , , , , , , - Abdominal Radiology 2019 cited by 120

  19. Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2021 cited by 68

  20. The Detection of Prostate Cancer with Magnetic Resonance Imaging-Targeted Prostate Biopsies is Superior with the Transperineal vs the Transrectal Approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-Institutional Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - The Journal of Urology 2022 cited by 66

  21. An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer

    Authors: , , , , , , , , , , , - European Journal of Cancer 2008 cited by 485

  22. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia ( BPH )

    Authors: , , , , , , , - British Journal of Urology 2013 cited by 258

  23. Clinical Validation of the Intermediate-risk Non–muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaboration

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - European Urology Oncology 2024 cited by 32

  24. Surgical checklist impact on recurrence‐free survival of patients with non‐muscle‐invasive bladder cancer undergoing transurethral resection of bladder tumour

    Authors: , , , , , , , , - British Journal of Urology 2018 cited by 75